Clinical Innovation Zone welcomes new tenant

The University of Glasgow has welcomed new tenant, Aurum Biosciences, to the Clinical Innovation Zone (CIZ), in the Imaging Centre of Excellence at its Queen Elizabeth University Hospital campus.

Aurum Biosciences is developing novel pharmaceuticals for use in a number of different clinical indications of high unmet medical need. Currently completing preclinical development of ABL101, its lead stroke management product, they envisage initiating clinical studies of efficacy and safety. Follow-on programmes include products for heart disease, cancer, epilepsy, and dementia.

Image of inside of Clinical Innovation Zone

Clinnovate Health, the provider of a highly sensitive and novel imaging technique for investigation and stratification of diseases has relocated within the CIZ, expanding its imaging service centre space, which works with partners across Europe.

Dr Carol Clugston, MVLS Chief Operating Officer, commented: “We are delighted to welcome Aurum Biosciences and support the relocation plans of Clinnovate Health within the CIZ. We are excited to further develop links and opportunities to support the success of all of our tenant organisations, as part of our ‘triple-helilx’ model.

Find out more about Aurum Biosciences and Clinnovate Health here: Aurum Biosciences  Clinnovate Health

First published: 28 July 2019